MENITORIX

This brand name is authorized in Ireland, UK.

Active ingredients

The drug MENITORIX contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Haemophilus type b polysaccharide conjugated to tetanus toxoid as carrier protein UNII `C9R35M8XV6` - HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
	Read more about
`2`	Neisseria meningitidis group C (strain C11) polysaccharide conjugated to tetanus toxoid as carrier protein UNII `ZT89E5A103` - NEISSERIA MENINGITIDIS GROUP C CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
	Read more about Meningococcal serogroup C polysaccharide vaccine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07AG53	Haemophilus influenzae B, combinations with meningococcus C, conjugated	J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AG Haemophilus influenzae B vaccines
Discover more medicines within J07AG53

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	99038

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.